DRG-MAOB-1 Selective MAO-B Inhibition for Neurodegenerative Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, such as Parkinson's and Alzheimer's, are long-term and economically challenging due to the lack of selective inhibitors for the MAO-B enzyme, which contributes to neurotransmitter depletion.
Innovation Solution
Development of a novel compound, DRG-MAOB-1, as a selective inhibitor of MAO-B enzyme to address the therapeutic need for neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective MAO inhibitors are used to treat neurodegenerative diseases, then MAO enzyme activity is inhibited, but selective inhibition of MAO-B cannot be achieved due to high sequence identity between MAO-A and MAO-B
Solution Approach 1:
The patent applies local quality by introducing a specific substituent group at a particular position in the molecular structure. The compound of formula I contains a specific substituent at the R1 position that creates selective interaction with MAO-B's active site, while maintaining overall structural simplicity. This localized structural modification enables selective inhibition without requiring complex molecular architecture.
Solution Approach 2:
The patent utilizes parameter changes by modifying specific molecular parameters (substituent type, position, and steric properties) to achieve selectivity. By changing the substituent at the R1 position from hydrogen to a specific group with particular steric and electronic properties, the compound achieves preferential binding to MAO-B over MAO-A, achieving selectivity through parameter optimization rather than structural complexity.
2Reliability
If existing MAO inhibitors are used for long-term treatment, then neurotransmitter depletion is prevented, but economic burden and treatment duration become challenging
Solution Approach 1:
The patent ensures continuity of useful action by designing a compound with sustained inhibitory activity against MAO-B. The compound of formula I maintains effective inhibition over extended periods, providing continuous prevention of neurotransmitter depletion without requiring frequent treatment interruptions or multiple medications, thereby reducing the economic and temporal burden of long-term therapy.
3Reliability
If MAO-B selective inhibitors are developed, then therapeutic benefit is improved, but development difficulty increases due to high sequence identity between isoforms
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional regions: a core scaffold that provides basic MAO inhibition and a specific substituent group at R1 that confers MAO-B selectivity. This segmentation allows independent optimization of each region - the core structure ensures general MAO inhibition while the R1 substituent provides selective interaction with MAO-B's unique features, simplifying the development process.
Solution Approach 2:
The patent uses an intermediary approach by introducing a specific substituent group at the R1 position that acts as a mediator between the compound and MAO-B's active site. This substituent serves as a molecular key that selectively interacts with MAO-B's unique structural features, enabling selective inhibition without requiring complex synthesis or multiple developmental stages.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DRG-MAOB-1 demonstrates a 13-fold higher potency in inhibiting MAO-B compared to MAO-A, providing a potential therapeutic benefit for neurodegenerative diseases.
Implementation Method 1
DRG-MAOB-1 acts as a selective inhibitor of MAO-B enzyme. MAO is responsible for the chemical breakdown of neurotransmitter molecules. The negative effects of neurotransmitter substances in the synaptic spaces are prevented by this way.
Data Source
AI summary
The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MAO-B.